TP53 mutation + ALK positive
|
NSCLC
|
TP53 mutation + ALK positive
|
NSCLC
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
TP53 mutation + ALK positive
|
NSCLC
|
TP53 mutation + ALK positive
|
NSCLC
|
ensartinib Resistant: C3 – Early Trials
|
ensartinib Resistant: C3 – Early Trials
|
TP53 mutation + ALK positive
|
NSCLC
|
TP53 mutation + ALK positive
|
NSCLC
|
lorlatinib Resistant: C3 – Early Trials
|
lorlatinib Resistant: C3 – Early Trials
|